To overcome these limitations, Antengene developed ATG-201, a “2+1” CD19 x CD3 TCE, which was evaluated in a series of in ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

Gain expert insights in this interview on achieving transfection success. Explore proven strategies to optimize your approach and enhance results.

During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with ...

Portal Bio’s microfluidic technology enhances drug discovery and cell engineering by enabling efficient, scalable molecular ...

More information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR. Targeted small molecule ...

ADC cytotoxicity was evaluated in both antigen-positive and antigen-negative cancer cell lines in vitro. Lysosomal cleavage of different linkers was evaluated in-vitro. ADC linker stability was also ...

If the European Commission approves this treatment, it'll be the first HER2-targeted agent for HER2-positive biliary tract cancer available to patients in the EU.

Results: Initially, using co-culture assays consisting of hematological ... We demonstrated that a direct cell-to-cell interaction was essential for pDC cytotoxicity, and that promoting stronger ...